Official Title A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir® System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease with Chronic Bronchitis (SPRAY-CB)

Purpose

The purpose of this study is to determine the safety and effectiveness of a device called the RejuvenAir® System, developed for patients with chronic bronchitis. The primary objective of this trial is to demonstrate the safety and effectiveness of the RejuvenAir® System for the treatment of adult subjects with a diagnosis of CB defined as COPD with classic 3 months of cough and sputum production for a minimum of 2 years who demonstrate ongoing symptoms of cough and significant mucus production. You will be in the study for approximately 36 months, including the screening period.

Could this study be right for you?

Inclusion Criteria:

1. Males and females 40-80 years of age
2. Must demonstrate daily cough and significant mucus production
3. Have had a diagnosis of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) for a minimum of two years. (CB is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded)
4. Smoking history of at least 10 pack years
5. Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study

Exclusion Criteria:

1. Have had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 4 weeks prior of initially planned study bronchoscopy
2. Diagnosis of Asthma
3. You have had any type of transplant procedure
4. Use e-cigarettes, vaping or inhaled substances not prescribed by a physician RejuvenAir® System
5. You are pregnant, nursing, or planning to get pregnant during study

* This is not a complete list of either inclusion or exclusion criteria

Age Range

40 and up

Official Title Evaluation of the efficacy of radiofrequency-based debridement vs. mechanical debridement for the treatment of articular cartilage lesions.

Purpose

The purpose of this study is to evaluate 2 different treatments, Mechanical Debridement (i.e., a mechanical shaver that removes areas of damaged tissue) and Radiofrequency Debridement (i.e., electrical energy that removes areas of damaged tissue), used to treat the chondral lesion in your knee.

Could this study be right for you?

You may be eligible for this study if you:

• Are 18 - 50 years of age
• Suspected chondral damage in the following locations where debridement is indicated:
  • Medial femoral condyle
  • Lateral femoral condyle
  • Trochlea
  • Patella
• 1 or more chondral lesion(s) as noted on MRI

Exclusion:

• Previous chondral treatment in the same compartment (prior debridement and lavage performed more than three months prior to baseline are acceptable)
• Pregnant and/or intending to become pregnant during this study period

Age Range

18 and up

Official Title A Multicenter, Randomized, Sham-controlled Study to Evaluate Safety and Efficacy After Treatment with the Nuvaira™ Lung Denervation System in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Purpose

The purpose of this research study is to evaluate the safety and efficacy of the Nuvaira System, which is made by Nuvaira, Inc., for Targeted Lung Denervation (TLD) Therapy.

The primary purpose of conducting this study is to see if TLD Therapy in addition to optimal medical care (daily breathing medications you have been prescribed by your doctor) is better at reducing a moderate or severe worsening of symptoms (known as an COPD flare-ups or exacerbations) and related hospitalizations than optimal medical care (daily breathing medications you have been prescribed by your doctor) alone.

Could this study be right for you?

Inclusion Criteria:

• Between 40 and 75 years of age
• Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the duration of the study
• Diagnosis of COPD with 30% ≤ FEV1 <60% of predicted and FEV1/FVC <70% (post-bronchodilator)
• SpO2 of at least 89% on room air at the time of screening
• Has a documented history of having minimally been taking a regular respiratory maintenance medication for at least 12 months at the time of consent; medications will be reviewed by study team
• If you have participated in a formal pulmonary rehabilitation program recently, program completion should have occurred more than 3 months prior to consent; if in a maintenance program, you will agree to continue your current program through your 12-month follow-up visit;
• Additional criteria will be reviewed by the study team

Involvement in this study will last approximately 62 months.

Age Range

40 and up

Official Title ABT-CIP-10300: Abbott DBS Registry of Outcomes for Indications over Time (ADROIT)

Purpose

The purpose of this study is to collect information and evaluate outcomes for Abbott Deep Brain Stimulation (DBS) systems that are approved and sold in your country.

In order to evaluate how the DBS system performs, data will be collected before, during and after DBS implant when you visit the study doctor. The data collected will include information on your movements, feelings, daily activities, and DBS program settings.

The information gathered in this study will add to the understanding of treatment options for future patients receiving DBS.

Could this study be right for you?

Inclusion Criteria:

• You are scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 3 months

Exclusion Criteria:

• You are currently enrolled or plan to enroll in another study that may alter the results of this clinical investigation
• You have another disease, conditions, or other medical, social, or psychological conditions that could limit your ability to participate in the clinical investigation or to satisfy follow-up requirements

Official Title Creation of a pediatric healthy control repository for clinical diagnostic immunology test development and validation

Purpose

A test for healthy adults from 19 - 75 years old to develop normal values for interpretation of immunological tests in adults with disorders of the immune system.

Voluntary participation involves blood draw at Nationwide Children's hospital. Qualified participants would be eligible to provide a sample every 2 months (not more than 6 times per year).

Could this study be right for you?

If you are:

• An adult 19 years of age or older
• Healthy with no significant medical diagnoses
• Have no chronic conditions that can affect results of immunological studies
• Not on any medication known to alter immune status or function
• Have not undergone recent surgery, chemotherapy, radiation or transplantation
• Non-smoker
• Body mass index (BMI) in healthy range
• No infections within last 2 months

Age Range

19 and up

Official Title ANB019-003: A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis

Purpose

This study is being done to assess the effects of the experimental study drug (ANB019) in patients with PPP.

Could this study be right for you?

• Must have a clinical diagnosis of PPP for at least 6 months prior to screening
• Must have active pustules on palms and/or soles of feet
• BMI must be within the range of 18-36 kg/m2
• Subjects must be in otherwise good health
• Must not have any suspected autoimmune disorder or immune deficiency
• No major surgeries in the past 4 weeks
• No history of malignancy in the past 5 years
• No history of drug, alcohol, or other substance abuse

Age Range

18 and up

Official Title STATBI: School Transitions after Traumatic Brain Injury

Purpose

The purpose of this study is to understand the best ways to help students return to school after brain injury of any severity. This is important to study because finding the best ways to help students go back to school right after brain injury, and over time, can help improve student success and recovery.

Your participation in the study would take place when you/your child begins the study and then at 3 months, 6 months, 12 months, 2 years (if applicable) and 3 years (if applicable) after the study starts.

Could this study be right for you?

• Students aged 5 to 18 years old
• In kindergarten through 12th grade
• Must Speak English
• Traumatic Brain Injury (TBI) of any severity
• Parent/caregiver is willing to share medical and academic information with the research team (all study activities are virtual/remote)

Age Range

5 and up

Official Title Creation of a pediatric healthy control repository for clinical diagnostic immunology test development and validation

Purpose

This study uses healthy children from newborns to 18 years old to help understand immune disorders. This study will compare healthy children and teens to children and teens with disorders of the immune system.

Volunteers will visit Nationwide Children's Hospital (NCH) for a blood draw either one time or not more than once every three months.

Could this study be right for you?

If your child is:

• Newborn to 18 years of age
• Healthy with no significant medical diagnoses
• Has no chronic medical conditions that can affect results of immunological studies
• Is not on any medication known to alter immune status or function
• Has not undergone recent surgery, chemotherapy, radiation or transplantation
• Has had no infections within the last 2 months

Official Title Cognition and Brain Circuitry

Purpose

The purpose of the study is to look at how our brain networks interact for different mental functions and how individual differences in brain structure and function determines individual differences in behavior. During this study, we use magnetic resonance imaging methods: functional magnetic resonance imaging (fMRI) and diffusion weighted imaging (DWI). Functional MRI (fMRI) and DWI are typical imaging methods that use a strong magnetic field and radio waves to make pictures of your body. The total length of the study will be between 3 and 4 hours, including up to 2 hours outside the MRI scanner and 2 hours in the scanner.

Could this study be right for you?

• Healthy adults between 18-40 years of age
• Have normal or corrected-to-normal vision

Age Range

18 and up

Official Title Mobile Health App as a Cardiotoxicity Symptom Logging Tool: Feasibility Pilot Study

Purpose

To evaluate the cardio-oncology patient population’s experience with using smart-phone technology as a part of self-management with their care through features such as symptom logging and education. Eligible patients will be asked to participate in a 30-minute virtual interview and/or a 60-minute virtual design or usability session to discuss their thoughts on a mobile app for cardio-oncology patients.

Could this study be right for you?

• English-speaking
• Prior cancer diagnosis
• Currently undergoing a cancer regimen that includes a targeted, biologic, radiation, and/or immune-based therapy (e.g., TKIs and/or ICIs).
• No pregnant females
• No prisoners

Age Range

18 and up

Official Title Immune Response in Adolescents

Purpose

Our goal in this study is to learn more about the immune system in adolescence and early adulthood. We are looking to enroll healthy children ages 12-18 years old.

Enrollment in the study will require 1 visit to Nationwide Children’s Hospital involving a blood draw and 2 nasal swabs.
The visit will take approximately 1- 1 ½ hour(s). We ask that the family brings a copy of the child’s immunization record to the visit.

Could this study be right for you?

Children will need to meet the following criteria to be in the study:

Inclusion Criteria:

• Parents/Legal guardian able and willing to sign informed consent and the child is willing to sign assent form for participation. All forms are in English.
• Healthy children, age 12-18 years old

Exclusion Criteria:

• Any chronic or congenital conditions that may potentially affect immune responses
• Cough, congestion, fever, rhinorrhea, rash and any other symptoms indicative of infection within the 2 weeks prior to enrollment sampling
• HIV, AIDS or other immunodeficiencies or any other condition that may affect their immune system
• Use of systemic steroids within 2 weeks prior to enrollment
• Immunization(s) within the last 30 days

Age Range

12 and up

Official Title ImproviNg The BrEast CaNcer Care DelivEry MoDel for Sex and Gender Minority Survivors (INTENDED for SGM)

Purpose

The long-term goal of this study is to improve decision quality and health-related outcomes for sexual gender minority (SGM) breast/chest cancer survivors. The goal is to evaluate important ways the current care model needs adjusted for SGM people, and how best to combine a socially important care model into clinical practice.

Survivors: Eligible participants will participate in a 90-minute focus group and online survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.

Clinicians: Eligible participants will participate in a 30-minute interview and brief survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.

Participation in this study will take no more than 1 hour and 30 minutes.

Could this study be right for you?

Survivors:

1. Self-identify as a member of the SGM community
2. Age ≥18 years at the time of signing the informed consent form
3. Breast/chest cancer survivor in active treatment or completed active treatment in the last 10 years (not including hormone therapy)
4. Be able to read and speak English
5. Have received care in the U.S.
6. Be able to participate in virtual meetings

Clinicians:

1. Physicians, advance practice providers, nurses, psychologists, social workers, therapists, technologists, and other trained clinical professionals
2. Provide care to individuals diagnosed with breast cancer in the U.S.
3. Be able to read and speak English
4. Be able to participate in virtual meetings

Age Range

18 and up